
At least 30% of patients with epilepsy have seizures that are incompletely controlled by medical therapy; thus, nonpharmacological options are important for comprehensive care.

At least 30% of patients with epilepsy have seizures that are incompletely controlled by medical therapy; thus, nonpharmacological options are important for comprehensive care.

Advances in the diagnosis and management of SMA include molecular genetic testing and the FDA approval of a disease-modifying therapy.

Published: May 14th 2019 | Updated:

Published: July 29th 2019 | Updated: